Navigation Links
Neurobiological Technologies Sets Date for Research and Development Day
Date:2/14/2008

EMERYVILLE, Calif., Feb. 14 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) today announced the date of its first annual Research & Development Day to be held on Tuesday, March 4, 2008. The event will take place from 8:00 to 9:30 a.m. at the Mandarin Oriental Hotel, 80 Columbus Circle, 36th Floor, South Salon, in New York City.

The focus of the meeting will be Viprinex(TM) (ancrod), NTI's compound for the treatment of acute ischemic stroke, currently in two Phase 3 clinical trials.

Questions about the R&D Development Day can be directed to Walter Kass, NTI Investor Counsel, 212-300-4708.

About Neurobiological Technologies, Inc.

NTI is a biopharmaceutical company focused on developing novel agents for central nervous system conditions. The Company's most advanced product candidate is Viprinex (ancrod), a novel multi-targeted agent currently undergoing pivotal Phase 3 clinical testing for the potential treatment of acute ischemic stroke.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
2. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
3. Neurobiological Technologies Sets Date for Second Quarter Financial Results
4. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
5. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
6. Neurobiological Technologies Announces Pricing of Its $60 Million Common Stock Offering
7. Neurobiological Technologies, Inc. (Nasdaq: NTIID)
8. Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
9. Neurobiological Technologies, Inc. Reports Receipt of Notice From Nasdaq
10. Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations
11. Emisphere Technologies to Web Cast BIO CEO & Investor Conference Presentation February 12
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 23, 2017  GlobeImmune, Inc. today announced it has ... of 12,835,490 shares of its common stock to NantCell, ... connection with the sale of its common stock, NantCell ... issue to GlobeImmune 200,000 shares, an estimated $2.0 million ... "We are pleased to enter into this strategic agreement ...
(Date:3/23/2017)... March 23, 2017 NetworkNewsWire Editorial Coverage  ... Cancer ... significant strain on health care systems, in terms of costs ... so too does the development of innovative and efficient therapies ... Among the many types of cancer treatments, a growing number ...
(Date:3/23/2017)... ... March 23, 2017 , ... Advanced Polymer Monitoring Technologies ... Dr. Sigmund “Sig” Floyd as Vice President ? Global Business Development. Dr. Floyd ... , “Dr. Floyd’s career has spanned 30 years in the chemicals and equipment ...
(Date:3/22/2017)... 2017  UBM and the Massachusetts Medical Device ... partnership and the third annual Massachusetts Medtech Week. Massachusetts ... st Annual MassMEDIC Conference held in conjunction ... 2017. MassMEDIC will feature a ... and CEO, Scott Whitaker , at its ...
Breaking Biology Technology:
(Date:2/27/2017)... --  Strategic Cyber Ventures , the industry,s first cybersecurity ... million investment in  Polarity , the first commercial human ... based and is led by cybersecurity veterans Tom ... Gula , also a longtime cybersecurity veteran and founder ... A round of funding. This new funding will be ...
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis ... Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen wurde ... um diese Prognose zu realisieren. ... Zu den Schwierigkeiten ... Mittel für die Biobank, die Implementierung Zeit sparender Technologien, ...
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
Breaking Biology News(10 mins):